Member Info for Bk2011

£865k cash balance as at the end of June 2024

This is a huge loss of trust between all shareholders and Steen. He thinks we're all fools. I hope Opti win and the fund raise is stopped.

I can't see how Steen keeps his job?

i have to agree. steen has ****ed off all existing holders. if he issues enough shares to his mates, whats stopping them buying probiotix on the cheap?

Huge dilution with the raise of funds at that price. Something stinks.

The receivables will likely increase as more distribution deals are agreed with more new partners across different regions.

How much they go up will depend on the payment terms and size of initial orders.

The spread is currently very reasonable

Perhaps a big order was received late in H1 ?

Steen may be able to grow sales but has a lot to learn about managing a plc and investor comms. Positive interims and sales almost doubling announced on a Friday of a bank holiday week in August. It's not a great day for positive news announcements.

Sales up but cash is down

It will come down to £18 to £20 per kg. As per the results rns

This could be a big deal

https://www.aquis.eu/stock-exchange/announcements/4758362

Wouldn't "SweetBiotix " be the trademark for the sweet fibers?

Thanks PeterBo. Did it say any reason for the buy recommendation?

The article is a year old but still informative and a good read.

Still buying this morning. I'm unable to get an online quote.

All looks a bit fishy

Many of us on here have been trying to find positives but given how the share price has resumed its down trend, there isn't much to shout about.

If the 2nd generation products are such a game changer and have huge potential, then why hasn't the market re-rated OptiBiotix? Why aren't the IIs owning more shares?

There are more questions than answers for me.

1.5m seems realistic this year but I recall a chart in an Investor Meet presentation showing revenue last year at approximately 1.7m. That never happened or even close.

The 1.5m is dependent on partners reordering and stock with CCL and Maxum having to be replaced. I figure the 1.5m estimate is only for slimbiome/leanbiome/optibiome?

Imo, OHara has no idea of how successful sweetbiotix and microbiome modulators will be and if there will be any contribution to current year sales from either.

He is heavily reliant on partners and have unreliable forecasts. They could very well be a huge success. If OHara thought this, he should be a lot more confident in how he writes the rns with more tangible target dates and revenue.

Make sure you ask the right questions

An 83% increase in H1 if repeated in H2 and full year would see 2023 revenue approx £2.3m.

I'd say that was satisfactory. Anything short of £2m would be disappointing imo.

It depends on your definition of satisfactory?

What revenue level for the full year 2023 is satisfactory?